Article

Osteosclerotic Change as a Therapeutic Response to Gefitinib in Symptomatic Non-Small Cell Lung Cancer Bone Metastasis

2022-06-24

Abstract excerpt

<title>Abstract</title> <p><bold>Background</bold>Despite improvement in the overall survival of patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation, the effects of EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment on bone metastasis remain unclear. This study investigated radiological responses to gefitinib regarding bone metastasis in the patients.<bold>...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5e0ee08a-f189-58ba-97ad-d83fb9b1c0ca
DOI: 10.21203/rs.3.rs-1500245/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Osteosclerotic Change as a Therapeutic Response to Gefitinib in Symptomatic Non-Small Cell Lung Cancer Bone MetastasisDOI 10.21203/rs.3.rs-1500245/v1Read

Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis.Semantic proximity Read

Clinical Implications of Isolated Bone Failure Without Systemic Disease Progression During EGFR-TKI Treatment.Semantic proximity Read

Femoral bone metastasis is a poor prognostic factor in osimertinib-treated patients with EGFR-mutated non-small cell lung cancer: a retrospective, multicenter studySemantic proximity Read

Femoral bone metastasis is a poor prognostic factor in osimertinib-treated patients with EGFR-mutated non-small cell lung cancerSemantic proximity Read

A case of lung adenocarcinoma with postoperative recurrence of multiple bone metastases that showed a gradual complete response to combined administration of erlotinib and zoledronic acid.Semantic proximity Read

Clinical Characteristics and Continued Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Administration in EGFR-mutated Non-Small Cell Lung Cancer with Skeletal Metastasis.Semantic proximity Read

Assessing EGFR-mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategy.Semantic proximity Read

Prognostic Factors in Lung Adenocarcinoma with Bone Metastasis Treated with EGFR-TKIs.Semantic proximity Read

Prediction of skeletal-related events in patients with non-small cell lung cancer.Semantic proximity Read

Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib.Semantic proximity Read

Osteoblastic progression during EGFR tyrosine kinase inhibitor therapy in mutated non-small cell lung cancer: a potential blunder.Semantic proximity Read